Researchers at the Wellcome Sanger Institute have identified genetic markers that may predict the progression of chronic blood cancers years before clinical symptoms appear. By tracking myeloproliferative neoplasms (MPNs) over decades, the study demonstrates that DNA mutations accumulate in distinct patterns that distinguish stable conditions from those likely to become more severe.
Traditionally, some patients lacking common genetic mutations have been diagnosed with blood cancer based solely on bone marrow cell appearance. This research suggests that many of these cases may reflect normal aging rather than a cancerous process. The findings support new guidelines advising doctors to categorize certain patients as having thrombocytosis without common mutations, preventing unnecessary and aggressive treatments.
By reconstructing genetic family trees of blood cells, the team observed how cancer clones evolve. Patients with stable disease showed few additional mutations over time, while those whose disease worsened displayed clear genetic shifts. This insight could allow clinicians to implement regular genomic monitoring, identifying high-risk individuals early to manage their care with greater precision.
This study draws on 25 years of patient data and nearly 8,000 blood tests. It marks a shift toward using genomic analysis to refine diagnostics and avoid overtreatment. The team suggests that these patterns could eventually become a standard part of hematology care, allowing for early intervention before a condition visibly deteriorates.